Navigation Links
Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
Date:1/28/2008

ies. Mr. Bennett earned his MBA from Pepperdine University and his B.S. in Industrial Technology from California State University, Long Beach.

"I am very excited to join Allos and lead the Company's manufacturing activities," said Mr. Bennett. "I believe Allos has the product candidates and leadership team to make a potentially significant impact in the development of new therapies for the treatment of cancer."

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkins Lymphoma (NHL). For additional information, please visit the Company's website at http://www.allos.com.

Safe Harbor Statement

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements relating to Mr. Bennett's potential impact on the future growth and success of the Company; the potential safety, efficacy and marketability of the Company's product candidates; and other statements that are other than statements of historical facts. In some cases, you can identify forward-looking s
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference
2. Allos Therapeutics Reports Third Quarter 2007 Financial Results
3. Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
4. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
5. Transition Therapeutics Announces Appointment of Vice-President of Business Development
6. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
7. Transition Therapeutics Announces Milestone Payment from Elan
8. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
9. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
10. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
11. Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... 2015 , ... Rio Salado College President Chris Bustamante announced on ... of Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado for the ... and impact through innovative technologies and strategies. , “I am very proud to be ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, ... Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your ... lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 ...
(Date:8/29/2015)... Raleigh, NC (PRWEB) , ... August 29, 2015 ... ... about how mesothelioma develops, may extend and improve the lives of patients, according ... its website. Click here to read the full article. , The ...
(Date:8/29/2015)... New York, NY (PRWEB) , ... August 29, 2015 , ... ... the unofficial end of summer (which astronomically, officially ends on September 22nd this year). ... no summer-induced cyber security hangovers linger on which could prove far more costly than ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 ... ... successful results and include treating the localized area with stretching, soft tissue manipulation. ... a neutral pelvic position have shown through research to improve treatment outcomes. ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... created the world's first canine clone, have cloned another breed ... the water and bird hunting// skills. ,A ... College of Veterinary Medicine of Seoul National University (SNU) cloned ... team, formerly led by the nation's disgraced stem cell scientist ...
... the earth, according to a study by Auckland University. This ... foods// cost substantially more. ,The study suggests that ... obtained for just $7 more a week. ... unit said, "Our research has shown that making some important ...
... in the January 24/31 issue of JAMA, Patients with ... West African// country of Senegal, had higher cure and ... communication with health personnel and community involvement. ... in the global fight against tuberculosis (TB). Reasons for ...
... moderation offers no harm to an expectant mother, in terms ... ,This study performed by researcher Dr Bodil Hammer Bech and ... online by the British Medical Journal. , ... commencing before 20 weeks into their pregnancy. ,The ...
... In a new study from The American Journal of ... and Ruqi Tang (Shanghai Jiao Tong University) present// evidence ... ,Specifically, their findings identify the chitinase 3-like ... that the genes involved in biological response to adverse ...
... may want to tune into more weather forecasts. //Weather patterns ... an epidemic is imminent because they determine the conditions for ... techniques can help quicken the response to viral outbreaks worldwide ... global warming is adding urgency to such strategies for fighting ...
Cached Medicine News:Health News:Seoul Lab Clones Poodle 2Health News:TB Intervention Program Improves Patient Outcomes 2Health News:Coffee Addicts With Baby, Take Heart 2Health News:Scientists Identify Gene That May Indicate Predisposition To Schizophrenia 2Health News:Experts Use Weather to Predict Disease 2
(Date:8/28/2015)... 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... the acquisition of leading OTC brands from GSK in ... transaction is a clear demonstration of Perrigo,s unique ability ... distribution network spanning 36 countries.  Perrigo ... commented, "We are excited to complete this transaction, which ...
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5DURECT to Participate in Upcoming Healthcare Conferences 2
... Simulation Corporation (MSC) is proud to offer innovative, guideline-based ... through the Health Care Innovation Challenge, announced on November ... Services. Simulation provides a unique, risk-free environment ... in managing patients with diagnoses associated with high mortality ...
... International Corporation (NASDAQ: PRXL ), a leading ... been selected as one of two strategic partners by ... services worldwide. PAREXEL will work with UCB ... to increase productivity and cost effectiveness. The ...
Cached Medicine Technology:Medical Simulation Corporation Offers Innovative Training Solutions for Healthcare Organizations Applying to the Department of Health and Human Services' Health Care Innovation Challenge 2UCB and PAREXEL Sign Strategic Partnership Agreement 2UCB and PAREXEL Sign Strategic Partnership Agreement 3UCB and PAREXEL Sign Strategic Partnership Agreement 4
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Latex Agglutination Slide Test for the Qualitative and Semi-Quantitative Determination of D-Dimer in plasma, 60 tests....
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasma with heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all fre...
Antigenic Total Protein S, ELISA Method...
Medicine Products: